Simplex Trading’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $87K | Sell |
8,900
-148,000
| -94% | -$1.28M | ﹤0.01% | 5727 |
|
|
2026
Q1 | $874K | Buy |
156,900
+25,100
| +19% | +$191K | ﹤0.01% | 2650 |
|
|
2025
Q4 | $970K | Buy |
131,800
+83,600
| +173% | +$511K | ﹤0.01% | 2636 |
|
|
2025
Q3 | $315K | Buy |
+48,200
| New | +$259K | ﹤0.01% | 4394 |
|
|
2024
Q4 | – | Sell |
-147
| Closed | -$1K | – | 9102 |
|
|
2024
Q3 | $1K | Sell |
147
-6
| -4% | -$75 | ﹤0.01% | 8203 |
|
|
2024
Q2 | $1K | Sell |
153
-600
| -80% | -$9.93K | ﹤0.01% | 8484 |
|
|
2024
Q1 | $17K | Sell |
753
-847
| -53% | -$14.9K | ﹤0.01% | 7219 |
|
|
2023
Q4 | $20K | Buy |
+1,600
| New | +$21.6K | ﹤0.01% | 6933 |
|
|
2023
Q3 | – | Sell |
-267
| Closed | -$7K | – | 9263 |
|
|
2023
Q2 | $7K | Sell |
267
-140
| -34% | -$6.03K | ﹤0.01% | 7686 |
|
|
2023
Q1 | $23K | Sell |
407
-940
| -70% | -$46.4K | ﹤0.01% | 6780 |
|
|
2022
Q4 | $68K | Buy |
1,347
+340
| +34% | +$23.6K | ﹤0.01% | 5510 |
|
|
2022
Q3 | $82K | Sell |
1,007
-753
| -43% | -$56.2K | ﹤0.01% | 5791 |
|
|
2022
Q2 | $119K | Buy |
1,760
+7
| +0.4% | +$642 | ﹤0.01% | 5331 |
|
|
2022
Q1 | $193K | Sell |
1,753
-1,160
| -40% | -$145K | ﹤0.01% | 5201 |
|
|
2021
Q4 | $280K | Buy |
2,913
+2,300
| +375% | +$229K | ﹤0.01% | 4671 |
|
|
2021
Q3 | $97K | Hold |
613
| – | – | ﹤0.01% | 6655 |
|
|
2021
Q2 | $94K | Buy |
+613
| New | +$89K | ﹤0.01% | 6822 |
|
|
2021
Q1 | – | Sell |
-3
| Closed | -$72K | – | 9432 |
|
|
2020
Q4 | $72K | Sell |
3
-4
| -57% | -$927 | ﹤0.01% | 5776 |
|
|
2020
Q3 | $154K | Buy |
7
+2
| +40% | +$489 | ﹤0.01% | 4429 |
|
|
2020
Q2 | $140K | Sell |
5
-5
| -50% | -$1.48K | ﹤0.01% | 4418 |
|
|
2020
Q1 | $290K | Sell |
10
-28
| -74% | -$7.72K | ﹤0.01% | 3189 |
|
|
2019
Q4 | $1.1M | Buy |
38
+27
| +245% | +$5.86K | ﹤0.01% | 2006 |
|
|
2019
Q3 | $153K | Sell |
11
-12
| -52% | -$1.63K | ﹤0.01% | 3852 |
|
|
2019
Q2 | $207K | Buy |
23
+13
| +130% | +$1.04K | ﹤0.01% | 3436 |
|
|
2019
Q1 | $90K | Hold |
10
| – | – | ﹤0.01% | 4454 |
|
|
2018
Q4 | $133K | Buy |
10
+5
| +100% | +$843 | ﹤0.01% | 3563 |
|
|
2018
Q3 | $124K | Buy |
5
+4
| +400% | +$1.11K | ﹤0.01% | 4200 |
|
|
2018
Q2 | $37K | Hold |
1
| – | – | ﹤0.01% | 5366 |
|
|
2018
Q1 | $6K | Buy |
+1
| New | +$199 | ﹤0.01% | 4489 |
|
|
2017
Q4 | – | Sell |
-3
| Closed | -$2K | – | 6330 |
|
|
2017
Q3 | $2K | Hold |
3
| – | – | ﹤0.01% | 5086 |
|
|
2017
Q2 | $8K | Sell |
3
-31
| -91% | -$4.59K | ﹤0.01% | 4171 |
|
|
2017
Q1 | $70K | Buy |
34
+33
| +3,300% | +$5.3K | ﹤0.01% | 2061 |
|
|
2016
Q4 | $1K | Sell |
1
-1
| -50% | -$135 | ﹤0.01% | 5420 |
|
|
2016
Q3 | $1K | Buy |
+2
| New | +$240 | ﹤0.01% | 5348 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 5322 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 5139 |
|
|
2015
Q4 | – | Sell |
-1
| Closed | -$16K | – | 5770 |
|
|
2015
Q3 | $16K | Sell |
1
-1
| -50% | -$267 | ﹤0.01% | 3012 |
|
|
2015
Q2 | $13K | Buy |
+2
| New | +$864 | ﹤0.01% | 2841 |
|
|
2015
Q1 | – | Sell |
-3
| Closed | -$1.29K | – | 3226 |
|
|
2014
Q4 | $1K | Buy |
+3
| New | +$1.7K | ﹤0.01% | 4157 |
|
Other funds holding KPTI
RCM
ACA
CCM
APM
Simplex Trading's KPTI Position: Q2 2026 in Review
Simplex Trading opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 24,086 shares worth $235K. The stake represents ﹤0.01% of the portfolio and ranks #4503 among its holdings. This is a return to the name: Simplex Trading previously reported a position in KPTI as recently as Q4 2025.
Simplex Trading first reported a position in KPTI in Q4 2014 and has held it in 31 quarters since. The position peaked at $498K in Q4 2019. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.
- Simplex Trading held 24,086 shares of Karyopharm Therapeutics worth $235K as of Q2 2026.
- Karyopharm Therapeutics was a new Simplex Trading position in Q2 2026.
- Karyopharm Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #4503 holding.
- Simplex Trading first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 31 quarters since.
- Simplex Trading's Karyopharm Therapeutics position peaked at $498K in Q4 2019.
- 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.